Biocartis
Edit

Biocartis

https://www.biocartis.com/
Last activity: 13.03.2023
Active
Categories: CareCommerceDiagnosticsHealthTechIndustryInformationPersonalPlatformTechnologyTime
Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market
Likes
1.21K
Followers
1.81K
Followers
26.58K
Website visits
13.7K /mo.
Mentions
48
Location: Belgium, Antwerp, Mechelen
Employees: 501-1000
Total raised: $375.93M
Founded date: 2007
Twitter
Facebook
LinkedIn
Youtube

Investors 6

Funding Rounds 6

DateSeriesAmountInvestors
11.05.2021Grant$1.7M-
27.04.2015-$108.76M-
05.09.2014-$83.54M-
06.11.2013Series E$40.55M-
12.12.2012Series D$45.63M-
17.11.2011Series C$95.75M-

Mentions in press and media 48

DateTitleDescription
13.03.20236 questions for SMEs and start-ups looking to become more sustainable: 'Find the right balance between workload and impact'You can find the original interview (NL) in Trends magazine here.
16.11.2022Press release Biocartis Group NV: Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximu...-
26.08.2022Global Liquid Biopsy Products Market Developing Sector Trends: RainDanceTechnologies, Biocartis, Qiagen, Guardant HealthLiquid Biopsy Products Market Liquid Biopsy Products Market Regional Standpoint: North America, Europe, Asia-Pacific, South America, Middle East & Africa NEW YORK, NY, UNITED STATES, August 26, 2022 /EINPresswire.com/ -- Global Liquid B...
10.01.2022BIOCARTIS : MEETS 2021 KEY OBJECTIVESPRESS RELEASE REGULATED INFORMATION 10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext...
10.01.2022Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVESPRESS RELEASE: REGULATED INFORMATION 10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronex...
10.11.2021Press release Biocartis Group NV: Biocartis Q3 2021 Business UpdatePRESS RELEASE: REGULATED INFORMATION 10 November 2021, 07:00 CET BIOCARTIS Q3 2021 BUSINESS UPDATE Mechelen, Belgium, 10 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronex...
02.11.2021Intervest realises fourth turnkey project for tenant Biocartis in MechelenBiocartis, located in the Intercity Business Park Mechelen, expands its existing office of 717m² with an adjacent office of 783m². Thanks to a turnkey solution, the new office was fitted out according to the "New Way of Working", ...
12.10.2021Biocartis : Disclosure of a transparency notificationPRESS RELEASE REGULATED INFORMATION 12 October 2021, 07:00 CEST Disclosure of a transparency notification Mechelen, Belgium, 12 October 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (E...
23.09.2021Biocartis : Announces Restart of its High-Throughput Cartridge Manufacturing LinePRESS RELEASE 23 September 2021, 07:00 CEST Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line Mechelen, Belgium, 23 September 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular di...
13.09.2021Biocartis : Disclosure of a transparency notificationPRESS RELEASE REGULATED INFORMATION 13 September 2021, 17:40 CEST Disclosure of a transparency notification Mechelen, Belgium, 13 September 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics compan...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In